UNSPSC 51434903: Aliskiren/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434903 Aliskiren/hydrochlorothiazide is a Commodity code covering pharmaceutical products — specifically combination antihypertensive medications — that state and local governments procure primarily through fire and rescue services, health and human services agencies, and cooperative purchasing arrangements. The work being solicited under this code spans direct medication procurement for emergency medical services (EMS) operations, wholesale distribution agreements for multi-state pharmacy benefit programs, and exploratory vendor-capability assessments for direct-to-manufacturer prescription fulfillment models. Issuing bodies include city fire departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering procurement on behalf of multiple participating jurisdictions. The code sees activity from both single-jurisdiction municipal buyers and broader cooperative vehicles designed to aggregate purchasing across state and local government entities.

Recent activity clusters in the South and upper Midwest. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications with a response deadline of April 8, 2026 and an estimated contract value of $40,000, requiring delivery within ten calendar days of order receipt and nine-month minimum shelf life; that solicitation included a 5 percent Small Local Business Enterprise (SLBE) bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026; vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement strategy development prior to formal solicitation.